All posts by : artem

A smile or a frown may reveal more than emotion alone. The faces that capture a child’s attention could provide important clues about their mental health and how depression develops.

New research from Binghamton University, State University of New York, suggests that depression may influence how strongly children focus on emotional expressions such as happy or sad faces. The pattern appears to differ depending on whether a child has a family history of depression.

Researchers at the Mood Disorders Institute at Binghamton University study how depression develops in children and adolescents, with particular attention to how family history and emotional experiences may influence vulnerability over time. By identifying these patterns while children are still developing, scientists hope to better understand who may be at greater risk and eventually improve prevention strategies.

“Most of the vulnerabilities that we focus on are still developing during this time period,” said Brandon Gibb, director of the Mood Disorders Institute and SUNY distinguished professor of psychology. “You can catch things as they’re developing, rather than only studying them once they’re already there and pretty stable.”

Following Children’s Attention Over Time

Earlier research has linked depression with greater attention to sad faces. However, those associations have generally been modest, and scientists have not been sure whether biased attention contributes to depression or develops because of it.

The Binghamton study was designed to investigate that question by tracking both depressive symptoms and attention patterns over time. According to the researchers, it is the first study to examine how changes in each may predict later changes in the other among children.

“The real novel piece is that we looked at these transactional relations,” said Kelly Gair, a PhD student at Binghamton and lead author of the paper. “Between attentional biases and depressive symptoms, we looked at the way that they were mutually predicting one another across the time points, which is especially novel and hasn’t been done before.”

The research team, which also included Leslie A. Brick from the University of New Mexico, followed 242 children and their mothers for two years. Participants were assessed every six months.

During each visit, children viewed pairs of faces on a screen. One face showed a neutral expression, while the other displayed an emotion (happy, sad, or angry). Eye tracking technology measured which face held the child’s attention and for how long.

Children in the study looked at faces conveying different emotions onscreen, and eye tracking technology recorded where their attention veered. Photo credit: NimStim Set of Facial Expressions (Tottenham et al., 2009).

Family History Changes the Pattern

The results suggest that increasing depressive symptoms do not affect every child’s attention in the same way. Family history appeared to play an important role.

Among children whose mothers had a history of major depressive disorder, rising depressive symptoms were associated with greater attention to sad faces. In other words, as these children experienced more symptoms themselves, their attention became increasingly drawn toward expressions of sadness.

“For those who are already at risk, the more these children experience depression themselves, the more they lose their ability to pull their attention away from the sad things around them,” Gibb said.

“We know that when you’re depressed, it changes what you pay attention to,” Gair said. “Our results suggest that these changes may be more long-lasting and may differ depending on family history. One thought is that for children of mothers with depression, who are exposed to more facial displays of sadness from interactions with their mom, these types of facial expressions become even more salient when they experience depression themselves, so their attention becomes increasingly stuck on sad expressions.”

Happy Faces May Lose Their Pull

A different pattern emerged among children whose mothers had no history of depression.

When depressive symptoms increased in these children, they did not become more focused on sad expressions. Instead, they paid less attention to happy faces.

“In our lower-risk children, what seems to be happening is that experiences of depression are eroding a protective factor, which is how much they pay attention to happy faces,” Gibb said.

The distinction suggests that depression may alter emotional attention through different pathways depending on a child’s underlying level of familial risk. For some children, sadness may become increasingly difficult to ignore. For others, positive emotional signals may simply become less likely to capture their attention.

A new approach to treating post-traumatic stress disorder (PTSD) has received FDA clearance, offering a personalized alternative for people who have not found sufficient relief through existing treatments. Developed by California-based Wave Neuroscience in collaboration with researchers at the Texas A&M Health Institute of Biosciences and Technology, the technology uses brain activity measurements to guide targeted magnetic stimulation.

Early clinical trial findings have been encouraging. According to Wave Neuroscience, patients experienced a 52% reduction in PTSD symptoms, while 68% achieved remission. The full findings are still being prepared for public release, but researchers believe the technology could significantly expand treatment options for millions of people.

The need for more effective PTSD care is substantial. In the United States, approximately 17.5 veterans die by suicide each day, and about 7% of veterans receive a PTSD diagnosis annually.

PTSD can develop after traumatic experiences such as military combat, serious accidents, natural disasters, or violence. An estimated 6% of Americans will experience PTSD during their lifetime, with higher rates among women and veterans.

Why Current PTSD Treatments Are Not Enough

Since PTSD was formally recognized as a diagnosis in 1980, treatment has largely centered on psychotherapy and medications known as selective serotonin reuptake inhibitors (SSRIs), including sertraline and fluoxetine.

Although these approaches can help, many patients continue to experience symptoms despite receiving treatment.

A 2020 review of PTSD medications found that patients reported improvements ranging from 6.8 to 10.1 points on symptom assessments. However, remission rates reached only 10.9% at most.

Wave Neuroscience reported substantially stronger preliminary outcomes in its clinical trial. Erik Won, DO, the company’s chief medical officer, described the results as a major advance over previously reported medication outcomes.

“In comparison to that study, our FDA trial reported a 52% reduction in symptoms, so more than a four-fold increase in efficacy,” Won said. “And more importantly, we saw 68% remission in our clinical trial. So, it’s really a quantum change, an inflection point in what we can offer to patients. From a clinical care perspective, that’s really meaningful.”

These findings are promising, although the results come from different studies and should not be interpreted as a direct comparison of treatment effectiveness.

How Personalized Brain Stimulation Works

The newly cleared system uses Magnetic e-Resonance Therapy (MeRT), a technology that combines measurements of brain activity with targeted magnetic stimulation.

First, an electroencephalogram (EEG) records the brain’s electrical signals. This information helps guide a personalized treatment plan using transcranial magnetic stimulation, or TMS.

During TMS, a coil positioned against the scalp delivers magnetic pulses that stimulate brain activity. The technique has already been used for other psychiatric conditions, including treatment-resistant depression.

What distinguishes MeRT is its use of an AI-assisted algorithm to customize stimulation protocols based on each patient’s brain activity rather than relying on a standardized approach.

“Transcranial magnetic stimulation, or TMS, was previously FDA cleared for treatment-resistant depression,” Won said. “By adding an augmented AI derived multivariate algorithm, we were able to personalize protocols that received FDA clearance for post-traumatic stress disorder, which should open up market access to about 13 million people who may be struggling with PTSD.”

Dr. Kenneth S. Ramos, a physician-scientist at Texas A&M Health with extensive experience in precision medicine, helped guide the research.

His work focuses on adapting medical care to the characteristics of individual patients instead of assuming that everyone will respond to the same treatment.

“Most clinical interventions for the treatment of PTSD do not work very well,” Ramos said. “So, this is a huge area where identifying interventions that could hopefully add quality of life to the people impacted by this disorder would be tremendously impactful.”

Wave Neuroscience CEO Fred Walke said Ramos was a natural fit for the project because of his expertise in personalized medicine.

Targeting PTSD With Greater Precision

Conventional TMS generally follows treatment protocols that are less individualized. MeRT builds on the same underlying technology but adjusts treatment according to the patient’s specific brain activity.

Ramos emphasized that even small biological differences between people can have major implications for medical care. Humans are approximately 99.9% genetically alike, yet the remaining 0.1% contributes to differences that can influence how individuals respond to treatment.

By accounting for these differences and tailoring stimulation to each person’s brain, researchers observed substantial reductions in PTSD symptom severity.

Ramos illustrated the distinction with an analogy involving a leaking roof.

He likened conventional TMS to covering a leak with a tarp to manage its effects. MeRT, in contrast, aims to provide a more targeted solution, comparable to identifying and replacing the damaged shingles responsible for the problem.

The broader goal is to move beyond treating patients with standardized protocols and toward interventions guided by measurable biological information.

From Breakthrough Designation to FDA Clearance

The regulatory process reached an important milestone in 2024, when MeRT received an FDA Breakthrough Device designation.

Dr. Rick Silva, executive director of clinical trials at the Texas A&M Health Institute of Biosciences and Technology, explained that the designation helps promising technologies move through regulatory review more efficiently.

It does not eliminate scientific or medical requirements. Instead, it can streamline communication and reduce administrative delays while preserving the standards needed for FDA clearance.

Silva said the progress was particularly meaningful because the project began during the COVID-19 pandemic and advanced through the regulatory process unusually quickly.

According to Silva, medical device development and clinical evaluation can often take around 10 years before clearance is obtained. This project completed the relevant process in just over two years.

He credited the experience and dedication of the Wave Neuroscience team with helping make that accelerated progress possible.

“I’ve been involved in probably close to 1,000 projects in academic medical centers over the years at varying degrees of depth and detail,” Silva said. “Patients are why I do what I do. It’s hard, and the failure rate is high, and it’s a lot of work. But when you get to a point where something is going to benefit patients, it’s very professionally gratifying and personally gratifying in many ways as well.”

A New Drug-Free Option for PTSD Patients

Dr. Israel Liberzon, distinguished professor of psychiatry and behavioral sciences at the Texas A&M Naresh K. Vashisht College of Medicine, served as the study’s lead psychiatrist and PTSD specialist.

He believes the clearance represents an important expansion of the available treatments for PTSD.

According to Liberzon, MeRT will become the only FDA-cleared nonmedication treatment specifically for PTSD once it reaches patients.

“Right now, the FDA has approved only two medications for PTSD,” Liberzon said. “It doesn’t mean that only two of them are used, but both are SSRIs. This is the first time that in addition to the medication, we have a non-medication option. There is psychotherapy that people use for PTSD, but psychotherapies require a lot of effort. People must participate actively, and many drop out because it’s too anxiety provoking. So now we have a unique alternative.”

In the clinical trial, participants received five treatment sessions each week over a period of five to six weeks.

Researchers reported that the improvements appeared to persist after the treatment sessions ended, suggesting the benefits may extend beyond the active therapy period.

For patients who struggle with medication side effects or find psychotherapy difficult to complete, a treatment based on personalized brain stimulation could provide another option.

“People living with PTSD have been left with trial-and-error treatment, medications and their side effects, and limited outcomes—even when treated by the most dedicated and experienced physicians,” Won said. “Wave’s FDA clearance signals a fundamentally different future: one in which PTSD can be objectively evaluated, precisely treated and meaningfully healed.”

Won also believes the technology could eventually be adapted to other psychiatric conditions, including depression and anxiety.

Could Personalized Brain Therapy Transform Mental Healthcare?

Dr. Leslie S. Prichep, chief scientific officer at Wave Neuroscience, sees the FDA clearance as an important step toward treatment decisions guided by objective measurements of brain function.

“The FDA clearance of the MeRT System reflects decades of scientific research using electrophysiological biomarkers in identifying abnormal brain activity profiles and guiding personalized intervention strategies,” Prichep said. “We believe this represents an important advancement toward a more objective, data-informed model of mental healthcare.”

Walke believes that giving patients clearer information about their brain activity could also help change public attitudes toward mental illness.

He compared the idea to treating a broken bone with a cast. By making mental health conditions easier to understand through measurable physical information, the company hopes to reduce stigma and help patients better understand their experiences.

“One of the goals of the company is to create a platform for mental healthcare that uses objective imagery to help patients understand why they’re experiencing life the way that they are,” Walke said. “That insight, compounded with proven technologies, promises incredibly high efficacy when personalized.”

An important next step will be ensuring that patients can actually obtain the treatment. Wave Neuroscience and Texas A&M Health are working with other stakeholders to expand availability and make the therapy more affordable through insurance coverage.

“Our hope is that this research and technology can be a catalyst for more widespread development and innovation of more effective, personalized and precision-guided treatments,” Won said. “This is proof positive that population-scale personalized medicine is not just an aspirational goal but is an achievable reality today.”

The project combines years of work across medicine, neuroscience, clinical research, and technology, all directed toward improving the lives of people affected by PTSD.

For Ramos, the opportunity to help veterans carries particular significance because of Texas A&M’s longstanding involvement in military and veteran initiatives.

“Texas A&M has a very rich history of military and veteran priorities,” Ramos said. “It’s a no-brainer that Texas A&M faculty would be interested in and supportive of an initiative that hopefully would bring positive solutions to a big problem. And anything we could do to help alleviate that problem is going to go a long way towards making a difference in the individual’s life as well as the people who are close to them. I feel very fortunate that we at Texas A&M were meaningfully involved in this project.”

Certain imagery-based psychotherapy techniques may help reduce fear of failure connected to painful childhood experiences, according to research from scientists at SWPS University and the Nencki Institute of Experimental Biology. The findings were published in the journal Frontiers in Psychology.

Difficult experiences early in life, including criticism, neglect, or severe reactions from caregivers, can influence emotional well-being and quality of life years later. How adults respond when a child makes a mistake may be especially important in shaping future patterns of thought and emotion. In some cases, those experiences can contribute to a fear of failure rooted in the belief that mistakes make a person less worthy in the eyes of others.

Researchers from the Poznań-based Laboratory of Affective Neuroscience at the Institute of Psychology, SWPS University, and the Laboratory of Brain Imaging at the Nencki Institute of Experimental Biology in Warsaw set out to determine whether imagery-based psychotherapy could reduce the ongoing effects of these painful memories on everyday life.

Testing Whether Memory Work Can Create Lasting Change

The randomized, controlled clinical trial included 180 young adults (between 18 and 35 years of age) who experienced fear of failure. During a two-week period, participants took part in four therapy sessions focused on difficult childhood memories involving criticism.

One group used the Imagery Exposure (IE) technique. Participants were asked to recall situations that had triggered fear or anxiety (the active control group).

A second group received Imagery Rescripting (ImRs), a technique designed to change the way a memory unfolds in the imagination. Participants brought a distressing experience to mind and then imagined a “defender” (e.g., a therapist) entering the scene, confronting the person delivering the criticism, and offering support to the child.

The third group used the same therapeutic approach, but with a 10-minute delay procedure (ImRs-DSR). Researchers designed this delay to interfere with the memory trace associated with the critical experience, potentially strengthening the intervention’s effects.

Participants completed questionnaires and interviews, while researchers also tracked physiological measures. Follow-up assessments took place three and six months later.

Fear, Guilt, and Stress Declined

All of the imagery-based approaches produced a significant and lasting reduction in fear of failure. Participants also reported lower levels of negative emotions, including sadness and guilt.

Their bodies appeared to respond differently as well. Physiological reactions to memories of criticism decreased, indicating that recalling distressing experiences no longer triggered the same level of intense stress. These improvements remained evident during follow-ups at three and six months, suggesting that the psychological effects were stable over time.

“The study shows that it is possible to reduce the intensity of negative emotions and arousal associated with memories of childhood criticism. Properly selected techniques can influence how these memories are experienced, making them less burdensome,” says study co-author Julia Bączek, a psychologist from the Laboratory of Affective Neuroscience at the Institute of Psychology, SWPS University.

Why Surprise May Matter

The researchers found that imagery rescripting worked especially well when it produced a moment of surprise. They linked this effect to prediction error, which occurs when there is a mismatch between what someone expects and what actually happens.

That unexpected difference may help loosen established emotional patterns and make it easier for the mind to replace old, painful responses with new ones.

“We have shown that a crucial part of imagery-based therapy is creating a discrepancy between what the patient expects and what actually happens in the new memory. It is this surprise that paves the way for a lasting therapeutic change,” says study co-author Stanisław Karkosz, a cognitive scientist from the Laboratory of Affective Neuroscience at the Institute of Psychology, SWPS University.

Researchers led by the University of Texas at Austin have created a soft wearable patch that improved REM sleep in real-world testing without medication or surgery. Known as NEUSLeeP, the device combines gentle ultrasound stimulation with electrodes that track brain activity as it happens. This allows the patch to influence deep areas of the brain involved in sleep while also monitoring the brain’s response.

“This is the first time we’ve been able to noninvasively target deep brain regions involved in REM sleep, while simultaneously monitoring brain activity,” said Kai Wing “Kevin” Tang, a recent UT biomedical engineering Ph.D. graduate who led the research effort. “Our skin-attached NEUSLeeP patch opens up new possibilities for understanding sleep and treating sleep disorders in home settings,” added Huiliang “Evan” Wang, assistant professor in the Cockrell School of Engineering’s Department of Biomedical Engineering, who supervised Tang’s work and served as the principal investigator (PI) directing the overall project.

Wearable Patch Helps People Reach REM Faster

The researchers tested the technology in a study involving 28 people, with the results published in Nature Communications. On average, participants entered REM sleep 43 minutes sooner and remained in that stage for about 16 minutes longer.

The benefits were observed in both healthy sleepers and participants experiencing some sleep difficulties. Users also described the patch as comfortable and safe, and the study reported minimal adverse effects.

Possible Benefits for Stress and Emotional Health

Among healthy participants, NEUSLeeP stimulation also increased heart rate variability, which is commonly used as an indicator of the body’s ability to respond to stress. Brain imaging revealed changes in circuits associated with emotion, raising the possibility that the technology could support mood regulation and psychological resilience.

“REM sleep is not just about dreaming — it’s about emotional reset and stress adaptation,” explained Gregory Fonzo, assistant professor in the Dell Medical School’s Department of Psychiatry and Behavioral Sciences and one of the project’s co-PIs. “By enhancing REM, we may help people better cope with stress and improve their overall well-being.”

REM sleep disruptions have been associated with depression, anxiety and post-traumatic stress disorder (PTSD). Current approaches to sleep problems, including medication and behavioral therapy, may cause side effects or may not directly address the underlying factors that interfere with REM sleep.

Future Trials for Insomnia, Depression and PTSD

The team plans to conduct larger studies to verify the initial results and evaluate whether NEUSLeeP could help people with PTSD, depression and chronic insomnia. The researchers also see potential uses in home sleep monitoring, neuroscience research and personalized sleep treatments.

“Our vision is a future where patients with mental health disorders can optimize their sleep with a noninvasive and safe treatment,” said Vincent Mysliwiec, M.D., a professor at UT Health San Antonio, a leading expert in sleep disorders, and another co-PI on the project. “This technology could help millions of people get the restorative sleep they need.”

Most of the brain’s roughly 100 billion neurons are produced before birth. However, the small number of new neurons that continue to form in the adult hippocampus may play an important role in protecting against depression, according to new research from Columbia University Vagelos College of Physicians and Surgeons.

The findings provide the first evidence that neurogenesis, the process of producing new neurons, stalls in the brains of adults with major depressive disorder. Researchers also identified molecular programs involved in controlling this process, offering potential clues for developing new treatments.

“Historically, depression was thought to be a disease of neurotransmitter deficiency, especially serotonin, but we now think that depression stems from multiple issues that affect our neurons’ ability to adapt to stress and changing environments,” says Maura Dupont, professor of psychiatry, who led the research.

“Without the ability to create new neurons, people with depression may not have the resilience to effectively adapt to the environment.”

How New Neurons May Shape Memory and Emotion

The researchers focused on the hippocampus, a brain region that plays a major role in episodic memory and emotional responses to the environment. It is also one of the few areas of the adult brain that continues to generate new neurons.

Although the hippocampus is not the only brain region involved in depression, its influence over both memory and emotion has made it an important area of study. Researchers believe changes there may contribute to the tendency of people with depression to interpret experiences more negatively.

“The hippocampus is important for our ability to distinguish between similar but different memories and separate the emotional connotation of past memories and current events,” Dupont says.

This ability is known as pattern separation. When it becomes impaired, individual memories and the emotions attached to them may become less distinct, allowing separate experiences to blend together.

“You may be out with a friend for lunch, but she’s tired and doesn’t talk much. With intact pattern separation, you remember this as a unique event. With impaired pattern separation, it becomes mixed with previous memories of feeling rejected, leading you to think, ‘They’re upset with me’,” Dupont explains. “And I see this a lot in my patients, where they can only retrieve negative information from their memories.”

Research in mice has shown that adult neurogenesis is necessary for pattern separation. A recent study involving patients with brain tumors, in whom neurogenesis was eliminated by radiation therapy directed at the hippocampus, suggests that the same relationship may exist in humans.

“It’s important to emphasize that we do not yet know the complete mechanism, particularly in humans, but the newborn neurons seem to enhance pattern separation because they are especially responsive to new experiences and can be incorporated into new memory circuits more easily, allowing new memories to be stored separately from the old ones,” Dupont says. “Turning neurogenesis back on may be a way to treat depression in some people by rewiring their hippocampus circuit.”

Depression Affects More Than New Neuron Growth

The researchers found that the changes linked to depression extended well beyond neurogenesis. New neuron formation operates within a larger hippocampal circuit that stores episodic memories along with their emotional significance, and molecular disruptions appeared throughout that system.

The affected genes included those involved in building new connections between neurons, supporting communication among brain cells, supplying cellular energy, and moving materials within cells.

The trisynaptic circuit, the hippocampus’s primary pathway for establishing new emotional memories, also displayed evidence of inflammation and cellular stress in people with depression.

To identify these changes, researchers studied nearly half a million brain cells collected from people with depression and control subjects shortly after each donor’s death.

Using an array of recently developed techniques, the team measured the activity of every gene within individual cells and examined whether cellular proteins had been altered. This enormous dataset allowed researchers to see what individual cells were doing and determine exactly where affected cells were located within the hippocampal circuit.

Genes, Environment, and the Biology of Depression

The analysis revealed altered activity in several genes whose genetic variants have previously been associated with major depression.

Other disrupted genes showed epigenetic changes that may reflect the influence of environmental factors. Epigenetic mechanisms can adjust how strongly genes are turned on or off without altering the underlying DNA sequence.

“These are like dimmer switches that control how active genes are, and they are affected by life experiences such as stress, learning, aging, chemicals, etc.,” Dupont says.

The diversity of molecular changes may also help explain why depression can look so different from one person to another.

“Overall, the wide range of effects we found could reflect different pathogenetic mechanisms, perhaps indicating that depression is not just one disease,” she adds.

Researchers still have only a limited understanding of depression’s underlying biology, according to Dupont. By defining the disorder more precisely at the cellular and molecular levels, studies like this one could eventually provide new targets for treatment.

Toward Molecular Subtypes of Depression

Dupont and her colleagues hope that depression could eventually be classified according to its molecular characteristics, much as cancer increasingly is today.

“We want to reclassify depression based on its molecular features, similar to what has been done in cancer,” Dupont says. “Classifying cancers based on their cellular characteristics, not their locations, has led to new and improved treatments. We hope the same will be true for depression and other psychiatric or brain diseases.”

Two people diagnosed with depression can experience vastly different symptoms. One might struggle with persistent anxiety and repetitive negative thoughts, while another may experience trauma related symptoms or substance abuse. But do these differences also appear in the way their brains function?

Researchers at the University of Helsinki investigated this question and uncovered a striking finding: people with the same depression diagnosis can have dramatically different patterns of brain activity. In some cases, communication between brain regions was unusually strong, while in others, it was weaker than normal.

Depression is a major global health concern. According to the World Health Organization (WHO, 2025), approximately 332 million (5.2%) adults worldwide are affected. In Finland, depression is the leading individual cause of both extended sick leave and disability pensions.

Brain Study Reveals Five Distinct Depression Profiles

To investigate the biological differences associated with depression, researchers examined brain activity in 263 people diagnosed with major depressive disorder and 75 healthy participants who served as a comparison group.

The analysis revealed five distinct groups based on differences in functional connectivity, a measure of how closely activity in different brain regions is coordinated. When two regions show synchronized activity, it suggests they are working together as part of a larger brain network. However, stronger connectivity does not necessarily mean the brain is functioning better.

“What was particularly interesting was the contrasting patterns of brain activity found under the umbrella of the same depression diagnoses. In some individuals, the functional connectivity between brain regions was stronger than usual, while in others it was weaker,” says Director Satu Palva of the Neuroscience Center, University of Helsinki.

These differences were also associated with particular symptoms. Participants in one group showed especially strong connections between brain regions, along with more pronounced substance abuse problems. Another group displayed weaker connections and a greater prominence of post-traumatic stress disorder (PTSD) symptoms.

The contrasting results could help explain why earlier studies examining the brains of people with depression have sometimes reached conflicting conclusions. If researchers study different combinations of patients, they may observe very different patterns, even though everyone involved has received the same diagnosis.

The findings add to growing evidence that depression may not have a single, consistent biological signature. Instead, the condition could involve several distinct patterns of brain function.

The Five Brain Patterns Linked to Depression

The researchers classified participants with depression into five groups based on how strongly different brain areas communicated and the frequencies at which their activity was coordinated.

Each group had a characteristic pattern of brain connectivity and associated symptoms:

Group 1: Strong connectivity and severe symptoms

Participants generally showed relatively strong connections between brain regions. This profile was associated with more severe symptoms across several areas, including depression, anxiety, rumination, and reduced ability to function in daily life. Rumination refers to repeatedly dwelling on distressing thoughts, worries, or negative experiences.

Group 2: Weaker connectivity and milder depression

This group was characterized by relatively weak communication between brain regions. Compared with the other groups, participants generally experienced milder symptoms.

Group 3: Widespread weak connectivity and trauma symptoms

People in this group showed reduced connectivity across substantial portions of the brain. Symptoms associated with post-traumatic stress disorder (PTSD) were particularly prominent.

Group 4: Mixed connectivity and multiple challenges

This profile combined unusually strong connections in some brain regions with weaker connections in others. Participants tended to experience more severe depression, greater substance abuse problems, and lower overall well-being.

Group 5: The strongest connectivity and substance abuse symptoms

Participants in the fifth group had the strongest connections between brain regions of any group identified in the study. Substance abuse was a particularly prominent issue, while trauma related symptoms were less pronounced than in the other groups.

Importantly, all five groups also showed differences from the healthy participants. These distinctions extended beyond whether brain connections were strong or weak. The groups also differed in which brain regions were involved and the frequencies at which their activity was synchronized.

Together, the patterns suggest that people diagnosed with depression may experience substantially different changes in how their brain networks operate.

Measuring Brain Activity With Millisecond Precision

To capture these differences, the scientists used magnetoencephalography (MEG), a brain imaging technique that detects extremely faint magnetic fields produced by electrical activity in the brain.

Unlike methods that track slower changes associated with brain activity, MEG can follow electrical signals as they unfold over extremely short periods. This makes it particularly useful for investigating the timing and coordination of communication between brain regions.

Using MEG, the researchers recorded brain activity in all 263 participants with depression and the 75 healthy control subjects.

“MEG enabled us to monitor electrical brain activity with millisecond precision, helping us get closer to what actually happens in the brain at any given moment. Previously, depression phenotypes have been studied using methods with slower responses,” Palva notes.

This high level of temporal precision allowed the team to examine rapid changes in brain activity that might be difficult to distinguish using slower measurement techniques.

By studying these fast signals, the researchers were able to identify differences not only in the strength of connectivity but also in the frequencies at which brain regions appeared to work together.

Could Brain Activity Lead to More Personalized Depression Treatments?

The discovery raises an important possibility for the future of mental health care: treatments might eventually be selected partly according to a person’s individual pattern of brain activity.

Today, finding an effective depression treatment can involve trying different medications or therapies and evaluating how well each works. Because patients can respond differently to the same treatment, identifying the most suitable approach is not always straightforward.

Brain activity measurements could eventually provide additional information to help guide these decisions. However, the researchers emphasize that their findings are not yet ready for clinical use.

“We’re not yet at the point where brain measurements can be used to choose the right treatment for patients, but the study does show one possible route,” Palva says.

A major long-term goal is to better understand how particular symptoms relate to the way brain networks function. Connecting these biological patterns with patients’ experiences could help researchers develop more precise ways to identify and characterize depression.

Eventually, such knowledge might allow doctors to determine which therapies are most likely to help individual patients, potentially reducing the amount of trial and error involved in treatment.

For now, the five brain profiles offer a different way to understand depression. Rather than assuming that one diagnosis corresponds to one underlying pattern of brain activity, the findings suggest that depression can involve markedly different biological changes, sometimes even in opposite directions.